Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YRYuhong RenFudan UniversityLCLuya ChengSun Yat-sen UniversityJXJiadai XuSun Yat-sen University

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows glofitamab improves overall survival in relapsed lymphoma, indicating favorable efficacy and safety profiles.

Key Points

  • To evaluate clinical outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma.
  • Retrospective study of patients treated with glofitamab regimens at Zhongshan Hospital, Fudan University.
  • Efficacy assessed using PET/CT and Lugano criteria, with toxicities evaluated by NCI-CTCAE 5.0.
  • Endpoints included best complete response rate, overall response rate, and survival outcomes.
  • Best complete response rate was 26.9% and overall response rate was 50.0%.
  • Median overall survival not reached with a follow-up of 5.5 months.
  • Most common adverse events included anemia (85.7%) and neutropenia (54.3%).

Cite This Study

Ren et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d740https://doi.org/10.1182/blood-2025-7257
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world efficacy, safety, and predictive factors for response to glofitamab in Chinese patients with relapsed/refractory aggressive B-cell lymphoma: A multicenter study2025
  2. 2Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  3. 3Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study2025
  4. 4Real-world outcomes of glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) in Relapsed/Refractory (R/R) aggressive B-cell lymphoma (BCL): A multicenter retrospective study from the United States2025
  5. 5Real-world outcomes of glofitamab monotherapy in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma: A multicenter Korean cohort2026